Catalyst Pharmaceuticals Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Catalyst Pharmaceuticals Inc 公司

Catalyst Pharmaceuticals, Inc. 是一家商业阶段的生物制药公司。该公司专注于开发和商业化用于治疗罕见和难治疾病的一流药物。其旗舰商业产品是 FIRDAPSE（氨苯吡啶）片剂 10 毫克 (mg)，获准用于治疗成人和 6 至 17 岁儿童的 Lambert-Eaton 肌无力综合征 (LEMS)。该公司还将 FYCOMPA（吡仑帕奈）CIII 作为处方药进行营销，可单独使用或与其他药物一起使用，用于治疗 4 岁及以上癫痫患者的局灶性发作（伴或不伴继发性全身性癫痫），以及与其他药物一起使用，用于治疗 12 岁及以上癫痫患者的原发性全身性强直阵挛性癫痫。其产品组合还包括 AGAMREE（vamorolone），一种用于治疗杜氏肌营养不良症 (DMD) 的 40 mg/ml 口服混悬液。 vamorolone 是一种用于治疗 DMD 患者的皮质类固醇药物。

公司简介

公司代码CPRX

公司名称Catalyst Pharmaceuticals Inc

上市日期Nov 08, 2006

CEOMr. Richard J. (Rich) Daly

员工数量181

证券类型Ordinary Share

年结日Nov 08

公司地址355 Alhambra Circle

城市CORAL GABLES

上市交易所NASDAQ Capital Market Consolidated

国家United States of America

邮编33134

电话13055292522

网址https://catalystpharma.com/

公司代码CPRX

上市日期Nov 08, 2006

CEOMr. Richard J. (Rich) Daly

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. Patrick James Mcenany

Non-Executive Chairman of the Board

4.28M

-4.46%

Dr. Steven R. Miller, Ph.D.

Executive Vice President, Chief Operating Officer, and Chief Scientific Officer

1.06M

+11.58%

Mr. Donald A. Denkhaus

Independent Director

495.08K

--

Dr. David S. Tierney, M.D.

Independent Director

379.62K

+6.75%

Mr. Brian D. Elsbernd, J.D.

Chief Compliance Officer, Chief Legal Officer

271.04K

+43.74%

Mr. Richard J. (Rich) Daly

President, Chief Executive Officer, Director

226.79K

+13.53%

Dr. Gary Ingenito, M.D., Ph.D.

Chief Medical Officer and Regulatory Officer

68.87K

--

Dr. Preethi Sundaram, Ph.D.

Chief Strategy Officer

41.08K

-8.72%

Ms. Molly Harper

Lead Independent Director

6.75K

--

Ms. Tamar Thompson

Independent Director

1.41K

--

名称

名称/职务

职务

持股

持股变动

Mr. Patrick James Mcenany

Non-Executive Chairman of the Board

4.28M

-4.46%

Dr. Steven R. Miller, Ph.D.

Executive Vice President, Chief Operating Officer, and Chief Scientific Officer

1.06M

+11.58%

Mr. Donald A. Denkhaus

Independent Director

495.08K

--

Dr. David S. Tierney, M.D.

Independent Director

379.62K

+6.75%

Mr. Brian D. Elsbernd, J.D.

Chief Compliance Officer, Chief Legal Officer

271.04K

+43.74%

Mr. Richard J. (Rich) Daly

President, Chief Executive Officer, Director

226.79K

+13.53%

收入明细

暂无数据

暂无数据

业务

地区

暂无数据

股东统计

更新时间: 8月16日周六

持股股东

股东类型

持股股东

占比

BlackRock Institutional Trust Company, N.A.

13.31%

The Vanguard Group, Inc.

7.14%

State Street Global Advisors (US)

4.48%

McEnany (Patrick James)

3.50%

Renaissance Technologies LLC

2.66%

其他

68.92%

持股股东

占比

BlackRock Institutional Trust Company, N.A.

13.31%

The Vanguard Group, Inc.

7.14%

State Street Global Advisors (US)

4.48%

McEnany (Patrick James)

3.50%

Renaissance Technologies LLC

2.66%

其他

68.92%

股东类型

持股股东

占比

Investment Advisor

44.99%

Investment Advisor/Hedge Fund

25.00%

Hedge Fund

8.17%

Individual Investor

6.23%

Research Firm

5.11%

Pension Fund

1.31%

Bank and Trust

0.48%

Private Equity

0.34%

Family Office

0.15%

其他

8.22%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

680

109.05M

89.10%

-4.69M

2025Q1

693

109.47M

89.76%

-3.79M

2024Q4

658

108.09M

89.06%

-2.57M

2024Q3

628

104.82M

88.36%

-8.18M

2024Q2

597

106.41M

90.13%

-15.99M

2024Q1

590

105.68M

89.66%

-4.79M

2023Q4

569

93.52M

87.71%

-15.08M

2023Q3

548

90.12M

84.55%

-19.61M

2023Q2

542

91.66M

86.51%

-22.59M

2023Q1

518

97.83M

92.70%

-11.38M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

BlackRock Institutional Trust Company, N.A.

16.42M

13.46%

-409.06K

-2.43%

Mar 31, 2025

The Vanguard Group, Inc.

8.47M

6.95%

+64.49K

+0.77%

Mar 31, 2025

State Street Global Advisors (US)

5.53M

4.53%

-266.12K

-4.59%

Mar 31, 2025

McEnany (Patrick James)

4.28M

3.51%

-200.00K

-4.46%

Jun 09, 2025

Renaissance Technologies LLC

2.96M

2.42%

+250.20K

+9.25%

Mar 31, 2025

Deerfield Management Company, L.P.

3.42M

2.81%

+289.14K

+9.23%

Mar 31, 2025

Geode Capital Management, L.L.C.

2.77M

2.27%

+100.08K

+3.75%

Mar 31, 2025

Fundsmith LLP

2.15M

1.76%

+2.15M

--

Mar 31, 2025

Morgan Stanley & Co. LLC

1.63M

1.34%

+261.85K

+19.08%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

2.19M

1.79%

-825.61K

-27.40%

Mar 31, 2025

持股ETF

更新时间: 9月6日周六

机构名称

占比

AAM Sawgrass US Small Cap Quality Growth ETF

1.4%

Invesco S&P SmallCap 600 GARP ETF

1.26%

First Trust Small Cap US Equity Select ETF

1%

Lattice Hartford Multifactor Small Cap ETF

0.89%

First Trust Active Factor Small Cap ETF

0.78%

Cambria Value and Momentum ETF

0.76%

WisdomTree US SmallCap Quality Growth Fund

0.31%

Gotham 1000 Value ETF

0.28%

Amplify Etho Climate Leadership U.S. ETF

0.26%

SPDR S&P SmallCap 600 ESG ETF

0.22%

AAM Sawgrass US Small Cap Quality Growth ETF

占比1.4%

Invesco S&P SmallCap 600 GARP ETF

占比1.26%

First Trust Small Cap US Equity Select ETF

占比1%

Lattice Hartford Multifactor Small Cap ETF

占比0.89%

First Trust Active Factor Small Cap ETF

占比0.78%

Cambria Value and Momentum ETF

占比0.76%

WisdomTree US SmallCap Quality Growth Fund

占比0.31%

Gotham 1000 Value ETF

占比0.28%

Amplify Etho Climate Leadership U.S. ETF

占比0.26%

SPDR S&P SmallCap 600 ESG ETF

占比0.22%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Catalyst Pharmaceuticals Inc

19.780USD

Catalyst Pharmaceuticals Inc

19.780

概览

公司

财务

分析